Department 1 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
Department 2 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
High Blood Press Cardiovasc Prev. 2024 Sep;31(5):485-492. doi: 10.1007/s40292-024-00664-y. Epub 2024 Aug 22.
Hypertensive heart failure (HHF) has a high incidence and poor prognosis.
This article evaluated the efficacy and safety of Vericiguat in HHF and analyzed the relationship between C-reactive protein (CRP) levels and patient prognosis.
110 HHF patients were divided into Placebo and Vericiguat groups. Cardiac function was assessed by echocardiography and 6-minute walk test (6MWT). Blood samples were collected to detect the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), endothelin (ET-1), nitric oxide (NO), and CRP.
Left ventricular end systolic diameter (LVESD) and left ventricular end diastolic dimension (LVEDD) were reduced, the left ventricular ejection fraction (LVEF) and 6MWT were increased, and the serum levels of NT-proBNP, cTnI, ET-1, NO, and CRP were decreased in Vericiguat group as against Placebo group; The total effective rate was 76.4% in Placebo group and 92.7% in Vericiguat group (P < 0.05). The adverse reaction rate was 10.9% and 9.1% (P > 0.05). The proportion of persons with poor prognosis and no improvement of cardiac function in patients with highly expressed CRP before treatment was higher as against patients with low expression of CRP (P < 0.05). Highly expressed CRP is an independent risk factor for poor prognosis.
Vericiguat is safe and effective in improving cardiac function in HHF patients.
高血压性心力衰竭（HHF）发病率高，预后差。
本文评估维立西呱在 HHF 中的疗效和安全性，并分析 C 反应蛋白（CRP）水平与患者预后的关系。
将 110 例 HHF 患者分为安慰剂组和维立西呱组。采用超声心动图和 6 分钟步行试验（6MWT）评估心功能。采集血样检测 N 端脑利钠肽前体（NT-proBNP）、心肌肌钙蛋白 I（cTnI）、内皮素（ET-1）、一氧化氮（NO）和 CRP 水平。
与安慰剂组相比，维立西呱组左心室收缩末期直径（LVESD）和左心室舒张末期直径（LVEDD）减小，左心室射血分数（LVEF）和 6MWT 增加，血清 NT-proBNP、cTnI、ET-1、NO 和 CRP 水平降低；安慰剂组总有效率为 76.4%，维立西呱组为 92.7%（P<0.05）。不良反应发生率分别为 10.9%和 9.1%（P>0.05）。治疗前 CRP 高表达患者预后不良和心功能无改善的比例高于 CRP 低表达患者（P<0.05）。CRP 高表达是预后不良的独立危险因素。
维立西呱可安全有效改善 HHF 患者的心功能。
